ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

In an effort to improve bladder preservation and quality of life, investigators are currently exploring the efficacy of risk-adapted treatment for patients with muscle-invasive bladder cancer after receiving a neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) regimen.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.